The trial data shows that patients receiving NX-1207 recorded significant quantitative improvement in the important symptoms of urgent need to urinate, and of frequency of urination.
Compared to baseline, symptoms of urgency to urinate were reduced by 47% at 90 days after a single treatment with NX-1207 (p less than 0.001), and this improvement was maintained in the majority of patients without further treatment at 12 months (41% improvement, p less than 0.001).
Compared to baseline, symptoms of frequency of urination were reduced by 43% at 90 days (p less than 0.001), and this improvement was also maintained without further treatment at one year in the majority of patients (35% improvement, p less than 0.001), the company said.
According to the company, NX-1207 has been shown to improve the signs and symptoms of benign prostatic hyperplasia (BPH), producing an improvement which has been statistically significantly better than double-blinded placebo and study controls and is higher than the improvement reported for approved drugs for BPH.